Regeneron, Sanofi’s Dupixent is one step closer to approval for young children in Europe

Shares of Regeneron Pharmaceuticals Inc.
REGN,
+0.07%
gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi
SAN,
-0.19%

SNY,
-0.66%,
for children as young as six months old. European regulators are expected to make a final decision in the coming months. Regeneron’s stock has gained 21.9% over the past year, while the broader S&P 500
SPX,
+0.25%
is down 6.6%.